Interaction of 8-anilinonaphthalene-1-sulfonate with SARS-CoV-2 main protease and its application as a fluorescent probe for inhibitor identification

Graphical abstract

Highlights

• •ANS binds the SARS-CoV-2 main protease and exhibits increased fluorescence.
• •ANS binding is competitive with baicalein that binds in the active site.
• •FMO-RIMP2/PCM calculation predicts that rutin is an inhibitor of the protease.
• •The ANS binding and kinetic assays confirm rutin as a protease inhibitor.
• •The ANS binding assay could be used to identify novel protease inhibitors.

Abstract

The 3C-like main protease of SARS-CoV-2 (3CL^Pro) is responsible for the cleavage of the viral polyprotein. This process is essential for the viral life cycle. Therefore, 3CL^Pro is a promising target to develop antiviral drugs for COVID-19 prevention and treatment. Traditional enzymatic assays for the identification of 3CL^Pro inhibitors rely on peptide-based colorimetric or fluorogenic substrates. However, the COVID-19 pandemic has limit or delay access to these substrates, especially for researchers in developing countries attempting to screen natural product libraries. We explored the use of the fluorescent probe 8-anilinonaphthalene-1-sulfonate (ANS) as an alternative assay for inhibitor identification. Fluorescence enhancement upon binding of ANS to 3CL^Pro was observed, and this interaction was competitive with a peptide substrate. The utility of ANS-based competitive binding assay to identify 3CL^Pro inhibitors was demonstrated with the flavonoid natural products baicalein and rutin. The molecular nature of ANS and rutin interaction with 3CL^Pro was explored with molecular modeling. Our results suggested that ANS could be employed in a competitive binding assay to facilitate the identification of novel SARS-CoV-2 antiviral compounds.

1. Introduction

In addition to vaccines, antiviral drug development is another frontier to combat the Corona Virus Disease 2019 (COVID-19). COVID-19 is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The virus produces polyproteins that require further processing by proteases to liberate functional proteins that are required for the viral life cycle [1]. Inhibition of the 3C-like protease (3CL^Pro), or the main protease, is a known approach to inhibit SARS-CoV-1 and Middle East Respiratory Syndrome (MERS) virus replication [2]. Therefore, there has been significant interest in the scientific community to identify inhibitors of SARS-CoV-2 3CL^Pro, thereafter referred to as 3CL^Pro, since the beginning of the outbreak [3], [4]. Several research groups have reported promising results in using protease inhibitors to control SARS-CoV-2 infection [3], [4], [5]. Novel computational methodologies have also been developed to screen for inhibitor of 3CL^Pro [6]. Still, the discovery of novel inhibitors is necessary to overcome the high mutation rate of the RNA virus [7].

Library of compounds isolated from natural sources offers a valuable source for 3CL^Pro inhibitor discovery. We have been interested in the exploration of local natural products as potential 3CL^Pro inhibitors. Traditional assays for protease inhibitor identification employ colorimetric or fluorogenic peptide substrates. This approach has been quite successful in identification of 3CL^Pro inhibitors [3], [4]. The peptide substrates could readily be synthesized by existing peptide synthesis methods. However, such services are not available in many developing countries with rich natural product resources, thus investigators are required to order synthetic peptides from abroad. With the COVID-19 pandemic, which results in laboratory and business closure, we have experienced a significant import delay of peptide substrates. Therefore, we seek to develop a new assay for 3CL^Pro inhibitor identification that could be used for natural product and chemical library screening. The enzyme inhibition activity could later be confirmed with a standard peptide-based assay. The assay should also be relatively inexpensive so that investigators with limited funding could employ the assay. Because the native cleavage sequences of 3CL^Pro (TSAVLQ-SGFRK and SGVTFQ-GKFKK, with - indicating the cleavage site)[8] contain a few hydrophobic amino acids and the active site of 3CL^Pro has positively charged histidine residues such as H41, H163, H164, and H172, we envision that the fluorescent probe 8-anilinonaphthalene-1-sulfonate (ANS) could be utilized in the desired assay.

ANS is a water-soluble molecule that exhibits increased fluorescence upon burial into a pocket in a protein [9]. ANS-based binding assay has been utilized to investigate protein–ligand interactions and protein unfolding processes [10], [11], [12], [13]. ANS has previously been employed to characterize the folding process of SARS-CoV-1 3CL^Pro, in which ANS binds to the exposed hydrophobic region when the protein is unfolded [14]. However, the interaction of ANS and the native 3CL^Pro has not yet been explored. If ANS could bind in the active site of 3CL^Pro, an increase in ANS fluorescence should be observed. Inhibitors of 3CL^Pro should be able to compete with ANS and resulted in a reduction in fluorescence. This equilibrium binding approach is also more convenient and requires less sophisticated equipment to perform than the time-sensitive enzyme kinetic screens or end point assays. In this work, we demonstrated that ANS could bind in the active site of 3CL^Pro by competition with the fluorogenic peptide substrate E(EDANS)TSAVLQSGFRK(DABCYL). In addition, ANS could compete with baicalein that is known to bind in the active site [15]. We also demonstrated the utility of the ANS-based binding assay for the identification of rutin as a 3CL^Pro inhibitor, as predicted by several computational studies [16], [17], [18], [19], [20], [21], [22]. The ANS-based competitive binding assay will be valuable in a cost-effective screen for novel 3CL^Pro inhibitors, especially when access to a peptide substrate is limited.

2. Results

The interaction of ANS with 3CL^Pro was first explored by monitoring the increased fluorescence in an ANS-3CL^Pro mixture compared to the solution with no 3CL^Pro (Fig. 1A). When excited at 345 nm, the increased fluorescence with an emission maximum at 455 nm was observed. Therefore, ANS could be shielded from the aqueous solvent when interacting with 3CL^Pro. The excitation and emission wavelengths at 345 and 455 nm, respectively, were used in subsequent experiments. The saturation binding curve suggested a simple binding interaction with the apparent dissociation constant (K_D) of 57 ± 7 µM (Fig. 1B).

Fig. 1.

A) Chemical structure and fluorescence emission spectrum of ANS (50 µM) bound to 3CL^Pro. B) Saturation binding curve to ANS to 3CL^Pro.

To determine whether ANS could bind in the active site of 3CL^Pro, inhibition experiments were performed using the fluorogenic peptide substrate E(EDANS)TSAVLQSGFRK(DABCYL) (Fig. 2). The non-linear fit of the kinetic data revealed the Michaelis constant (K_M) for the fluorogenic substrate to be 51 ± 9 µM. The addition of ANS and the non-linear fit of the resulting kinetic data to the competitive inhibition model gave the inhibitory constant (K_I) of 188 ± 24 µM.

Fig. 2.

Lineweaver–Burk plot of an initial rate enzyme kinetic experiment of 3CL^Pro at different substrate concentrations with ANS presented at 0, 250, and 500 µM. Trend lines were created with parameters derived from non-linear fit of the original data.

To demonstrate the utility of ANS as a fluorescent probe to identify a 3CL^Pro inhibitor, we performed competitive binding and competitive inhibition experiments with baicalein and rutin (Fig. 3A). Baicalein is a flavonoid natural product known to inhibit 3CL^Pro [15]. X-ray crystallography revealed that baicalein binds in the active site of 3CL^Pro. Thus, the reduction of ANS fluorescence by baicalein should be evidence that ANS binds in the active site of 3CL^Pro. Indeed, the reduction of ANS fluorescence was observed as baicalein was titrated (Fig. 3B). For the ANS competitive binding assay, the half-maximal inhibitory concentration (IC₅₀) of baicalein was 42 ± 2 µM, and the corresponding K_I obtained from the Cheng-Prusoff equation was 15.2 ± 0.7 µM. Inhibition of 3CL^Pro by baicalein was also confirmed in an activity assay using the fluorogenic peptide substrate E(EDANS)TSAVLQSGFRK(DABCYL) (Fig. 3C). For the enzyme activity inhibition assay, IC₅₀ for baicalein was 280 ± 1 µM, and the corresponding K_I obtained from the Cheng-Prusoff equation was 188 ± 1 µM.

Fig. 3.

A) Chemical structures of baicalein and rutin. B) Reduction in 3CL^Pro-bound ANS fluorescence upon titration of baicalein and rutin. ANS concentration was at 100 µM. C) Inhibition of 3CL^Pro enzymatic activity by baicalein and rutin. The fluorogenic substrate concentration was at 25 µM.

Similar to baicalein, rutin is a flavonoid previously predicted computationally to bind and inhibit 3CL^Pro [18], [19], [20], [22], [23]. We have also independently predicted binding of rutin within the active site of 3CL^Pro using a molecular docking (Fig. 4). The binding energy was −10.0 kcal/mol. Enhanced binding interactions were found for rutin binding (hydrophobic contacts with the 13 residues in chain A and 3 residues in chain B as well as four hydrogen bonds at the disaccharide rutinose (2.7–2.9 Å). This is somewhat inconsistent with the previous in silico studies using only one chain of protease (Table 1). Our results suggest that the termini of the other chain in the 3CL^Pro dimer are important in the interactions with rutin.

Fig. 4.

FMO-RIMP2/PCM pair interaction energy (PIE^total) and energy components (electrostatic intyeraction ($E_{\mathit{IJ}}^{\mathit{ES}}$), charge transfer with higher-order mixed terms energies ($E_{\mathit{IJ}}^{\mathit{CT}+mix}$) dispersion ($E_{\mathit{IJ}}^{\mathit{DI}}$), exchange-repulsion ($E_{\mathit{IJ}}^{\mathit{EX}}$), and the PCM solvation effect ($G_{\mathit{Sol}}^{\mathit{PCM}}$)) for rutin interacting with individual residues of dimeric SARS-CoV-2 3CL^Pro. Rutin orientation and interactions at the active site of SARS-CoV-2 3CL^Pro are shown above, where the green dashed line represents the hydrogen bonding. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Table 1.

Predicted binding mode of rutin toward SARS-CoV-2 3CL^Pro.

Model	PDB ID	Software	Hydrogen bonding residues	Reference
dimer	6LU7	Autodock Vina	L141, S144, G302 (Chain B)	This study
monomer	6LU7	Autodock Vina	T26, Y54, L141, M165, E166	[18]
monomer	5R82	Autodock Vina	T45, G143, E166	[17]
monomer	6LU7	Autodock Vina	D178, R188, T190	[20]
monomer	6LU7	Autodock Vina	N.A.	[21]
monomer	6LU7	Glide	N142, G143, C145, T190	[22]
monomer	6LU7	LeDock	F140, E166, T26, L141, S144, C145, H163	[19]

To gain further insight into the interaction between rutin and 3CL^Pro at the atomic level, the fragment molecular orbital calculation with a high level of theory (FMO-RIMP2/PCM) was applied on the rutin-3CL^Pro complex. The total pair interaction energy (PIE^total) and energy contribution from the residues within the 7-Å sphere of rutin were plotted in Fig. 4, where the negative and positive values represent the ligand stabilization and destabilization, respectively. Only the residues with energy contribution ≤ -5.0 kcal/mol and ≥ 5.0 kcal/mol were discussed. The PIE^total value of −85.19 kcal/mol indicates that the complexation between rutin and dimeric 3CL^Pro was likely stable. Among the 44 fragments (amino acid residues in the FMO calculation), there are 12 residues in both chains (chain A: L27, H41, Y54, L141, C145, M165, E166, H172, D187, R188; and chain B: V303, F305), contributed to rutin binding with energy stabilization in a range of −5.2 to −25.5 kcal/mol. E166 provides most significantly to the high binding affinity of rutin in terms of electrostatic, charge transfer, dispersion, and solvation effect. The catalytic dyad H41 and C145 play a vital role in binding with the quercetin moiety of rutin. Although rutin is likely to be a non-covalent inhibitor, it shares corresponding binding patterns with the reported inhibitors of SARS-CoV-2 3CL^Pro [24].

Despite predictions from other research groups, including us, no experimental demonstration of rutin inhibitory activity against 3CL^Pro has been reported. To experimentally confirm that rutin could bind 3CL^Pro, we performed the ANS-based competitive binding assay. Titration of rutin into a solution of ANS-bound 3CL^Pro resulted in the reduction of ANS fluorescence. IC₅₀ of rutin was 31 ± 1 µM, and the corresponding K_I obtained from the Cheng-Prusoff equation was 11.3 ± 0.4 µM for the ANS competitive binding assay (Fig. 3B). Enzyme inhibition was also confirmed using the fluorogenic peptide substrate (Fig. 3C). For the enzyme activity inhibition assay, IC₅₀ for rutin was 104 ± 1 µM, and the corresponding K_I obtained from the Cheng-Prusoff equation was 69 ± 1 µM.

To obtain structural information for interaction between ANS and rutin, we attempted to crystallize these compounds with 3CL^Pro. Crystals that diffracted to around 1.5 Å were readily obtained (Table 2). However, ANS or rutin was not observed in the active site, but a molecule of DMSO was present instead (Fig. 5A). We initially speculated that DMSO might interfere with ANS binding to a certain extent. However, the ANS saturation binding curve (Fig. 1B) was obtained in the presence of 1% DMSO as in all the assay buffers. The omission of DMSO for the saturation binding experiment yielded a virtually identical curve (data not shown). The crystal structure of baicalein is already available for comparison (Fig. 5B) [15]. To obtain an ANS-bound 3CL^Pro structure, we performed molecular docking (Fig. 5C). The binding energy was −6.9 kcal/mol. ANS showed hydrophobic contacts with 9 residues (H41, M49, F140, L141, C145, H164, M165, E166, and Q189) in chain A, including a hydrogen bond between its sulfonate group with catalytic H163 (3.1 Å), and with the N-terminal serine residue of chain B. The structure of the rutin-3CL^Pro complex from docking mentioned previously was displayed in the same orientation for comparison (Fig. 5D). From our models and the crystal structure of the baicalein-3CL^Pro complex, ANS, baicalein, and rutin occupy an overlapping space in the active site of 3CL^Pro, which is also the space occupied by the peptidomimetic covalent inhibitor N3 (Fig. 6) [3].

Table 2.

Crystallographic data collection and refinement statistics.

Data collection statistics
Wavelength (Å)	0.97872
Resolution range (Å)a	27.57–1.45 (1.47–1.45)
Space group	C 2
Unit cell dimensions	113.2, 53.0, 44.7 90.0, 103.1, 90.0
Total number of reflections	339,475 (16,721)
Number of unique reflections	43,879 (2,124)
Multiplicity	7.7 (7.9)
Completeness (%)	96.1 (93.8)
Mean I/σ(I)	15.3 (2.2)
Wilson B factor (Å2)	12.21
Rmerge	0.077 (1.035)
Rmeas	0.082 (1.108)
Rpim	0.030 (0.394)
CC1/2	0.999 (0.803)
Refinement Statistics
Resolution range (Å)a	27.57–1.45 (1.50–1.45)
R-factor	0.1664 (0.2567)
R-free (5%)	0.2010 (0.2731)
Number of atoms	2,935
Protein	2,473
DMSO	16
Water	446
Number of protein residues	305
RMSD for bonds (Å)	0.005
RMSD for angles (deg)	0.822
Estimated coordinate error (ML, Å)	0.14
Ramachandran favored (%)	98.68
Ramachandran outliers (%)	0.33
Average isotropic B factor (Å2)	20.96
Protein	18.86
DMSO	27.57
Water	32.37
PDB accession code	7DJR

^aStatistics for the highest-resolution shell are given in parentheses.

Fig. 5.

A) Crystal structure of 3CL^Pro crystallized in the presence of 5 mM ANS but has DMSO (green) bound instead of ANS. B) Crystal structure of 3CL^Pro with baicalein bound (PDB ID 6M2N). C-D) Conformations of ANS and rutin binding to 3CL^Pro by molecular docking. Potential non-covalent interactions are shown as dash lines with distances in Ångstrom (Å). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Fig. 6.

Position of ANS and rutin in the active site compared to the peptidomimetic N3 inhibitor.

3. Discussion

ANS could bind 3CL^Pro, which resulted in an increased fluorescence at 455 nm. Although ANS has been used previously to study the unfolding process of SARS-CoV-1 3CL^Pro, our results demonstrated that ANS could bind to a pocket in the native 3CL^Pro. To confirm that the ANS binding pocket is within the active site of 3CL^Pro, we first showed that ANS is a competitive inhibitor of 3CL^Pro. Using the fluorogenic peptide substrate, we observed a reduction in catalytic activity in the presence of ANS that could be fitted with the competitive inhibition model. Therefore, ANS binding site overlaps with the substrate-binding site.

The binding affinity of ANS towards 3CL^Pro could be extracted from the saturation binding curve and the competitive inhibition experiment. However, the K_I value obtained from the competitive inhibition assay was higher than the K_D value obtained from the saturation binding curve of ANS to 3CL^Pro. Several factors might have resulted in the discrepancy, including the difference in assay conditions. The major factor could be the poor solubility of the peptide substrate that limits data points at high substrate concentrations in the ANS competitive inhibition experiment. The maximum velocity estimation and K_M may not be accurate. Another potential source of affinity discrepancy could be due to multiple ANS binding sites on 3CL^Pro. It is possible that 3CL^Pro possesses a high-affinity binding site for ANS that does not affect the 3CL^Pro catalytic activity. We cannot completely rule out this possibility with the current data. However, the saturation binding curve is evidently hyperbolic. Thus, even if there are multiple binding sites, the binding affinities are likely similar. Therefore, the K_D value obtained from the saturation binding curve might reflect the binding affinity of ANS to 3CL^Pro more accurately than the K_I value from the competitive inhibition experiment.

To confirm that ANS indeed binds in the substrate-binding site, we investigated whether baicalein could compete with ANS binding. Baicalein had already been crystallized in complex with 3CL^Pro [15]. Thus, the binding site is known. Baicalein had also been shown to inhibit 3CL^Pro in enzymatic inhibition assays [15] including one independently reported by us. Therefore, baicalein could be used to validate the ANS utility in inhibitor identification. Indeed, baicalein could compete with ANS for 3CL^Pro binding. The K_I value of baicalein from the ANS competitive binding assay (11.3 µM) is comparable with the K_D value previously obtained from an isothermal titration calorimetry experiment (4.03 µM) [15]. Therefore, the ANS-based competitive binding assay yielded similar results to other techniques used to identify 3CL^Pro inhibitors.

We next applied the ANS-based competitive binding assay to show that rutin is an inhibitor of 3CL^Pro. Rutin has been predicted computationally by multiple research groups to be a 3CL^Pro inhibitor (Table 1). We have shown that rutin is competitive with both ANS and the fluorogenic peptide substrate. Therefore, we have both demonstrated the inhibitory activity of rutin and also shown that ANS could be used to identify novel inhibitors.

To investigate the molecular details of the interaction between ANS and rutin with 3CL^Pro, we attempted to crystallized this compound with 3CL^Pro. However, only the DMSO-bound structure was obtained. Therefore, we employed computational methods to investigate the 3CL^Pro-ligand interactions. Both ANS and rutin binds in the active site overlapping the known baicalein[15] or N3 inhibitor binding site[3]. The sulfonate group of ANS interacts with a histidine residue, H163, as expected. H163 is not a part of the catalytic dyad but forms the S1 pocket for substrate binding and is also recognized by the γ-lactam moiety of the N3 inhibitor. Rutin interacts mainly with the S1 and S2 pockets, and also interact with residues from the neighboring 3CL^Pro subunit.

Compared with the crystal structure of DMSO-bound 3CL^Pro, other ligand-bound structures required movement of the M49 side chain and distortion of the corresponding helix. This required conformational change may explain why we did not observe any ligands in the DMSO-bound, tightly packed C2 crystal form. The baicalein-bound crystal was in the P1 space group, in which the M49-containing helix is more solvent-exposed. Therefore, further crystal engineering may be required to obtain new crystal forms for the ANS- and rutin-bound 3CL^Pro structures. In addition, because it appeared that the readily obtained C2 crystal form has ligand bias, it may be beneficial for future investigators to screen for other crystal forms to be used in other inhibitor discovery approaches.

In conclusion, ANS could be used in a competitive binding assay to identify ligands that interact with 3CL^Pro in the active site. Using baicalein as a model compound with a known binding location and 3CL^Pro inhibitory activity, we showed that ANS binding was competitive with baicalein. Thus, ANS likely binds in the active site of 3CL^Pro. We also applied this methodology to demonstrated that rutin, a compound predicted to bind and inhibit 3CL^Pro, was indeed binding competitively with ANS and could inhibit 3CL^Pro activity. These results demonstrated the utility of ANS in the identification of potential 3CL^Pro inhibitors. This inhibitor identification strategy could be employed when researchers have limited access to peptide-based protease assays.

4. Materials and methods

4.1. Protein expression, ANS binding assay, and enzyme kinetics

SARS-CoV-2 3CL^Pro with no tags at the termini was expressed, purified, and stored exactly as previously described for SARS-CoV-1 3CL^Pro [25]. The gene was synthesized and codon-optimized for expression in Escherichia coli based on the amino acid sequence in GenBank accession number NC_045512. 3CL^Pro concentrations were determined using the absorbance value at 280 nm and the extinction coefficient of 32,890 M⁻¹ cm⁻¹.

All assays were performed with BioTek Synergy H1 microplate reader using PBS with 1 mM DTT and 1% DMSO as the reaction buffer. The volume was fixed at 100 µL. ANS binding assay was performed with 3CL^Pro at 5 µM. The excitation and emission wavelengths used were 345 and 455 nm, respectively. For enzyme kinetics, the fluorogenic substrate E(EDANS)TSAVLQSGFRK(DABCYL) (Biomatik) was used with 0.2 µM of 3CL^Pro. The excitation and emission wavelengths employed were 340 and 490 nm, respectively. GraphPad Prism 8 (San Diego, California USA, www.graphpad.com) was used for graphing and non-linear fit. [26]

4.2. X-ray crystallography

3CL^Pro was crystallized as described previously (100 mM MES pH 6.5, 15% PEG 4,000, and 5% DMSO)[27] but in the presence of 5 mM ANS. Microseeding was required to obtain crystals suitable for data collection. Crystals were cryoprotected with the crystallization buffer with 5 mM ANS but the PEG 4,000 concentration raised to 35%. Diffraction data were collected at the Life Sciences Collaborative Access Team beamline 21-ID-F (Advanced Photon Source, Argonne National Laboratory). The data were indexed and integrated with XDS [28]. Space group determination and scaling were performed with AIMLESS [29]. Molecular replacement phasing was accomplished with Phaser [30] using a previously reported SARS-CoV-2 3CL^Pro crystal structure (PDB ID 5RE9) as a search model. Refinement and model adjustments were performed with phenix.refine [31], [32] and COOT [33] respectively. Structure figures were created with UCSF Chimera [34]. The crystal structure and the associated experimental data were deposited at the Protein Data Bank under the accession code 7DJR.

4.3. Prediction of ligand–protein binding and interactions

The 3D structures of the ANS and rutin were built by GaussView 6.0.16 and then optimized with DFT-B3LPY/6–31 g(d) basis set using gaussian 16 [35]. The 3CL^Pro protein covalently bonded with the N3 inhibitor was retrieved from the protein databank (PBD ID 6LU7) [3]. The prepared protein structure without inhibitor binding was taken from our previous studies [24], [36]. To construct the initial structure of the ligand-3CL^Pro complex, the optimized structures of deprotonated ANS and rutin were separately docked into the binding site of N3 inhibitor using AutoDock Vina 1.1.2 according to the standard procedure [37]. The ligand orientation with the highest binding affinity was chosen for ligand–protein analysis and further ab initio fragment molecular orbital (FMO) calculation [38], [39], [40].

To provide a detailed insight into the binding of rutin to 3CL^Pro, the pair interaction energy (PIE) calculation using the second-order Møller–Plesset perturbation theory (MP2) with the resolution-of-the-identity (RI) approximation and polarizable continuum model (PCM) solvation effect (FMO-RIMP2/PCM) was carried out by GAMESS software [41], [42] with the 32 cores computer cluster using a generalized distributed data interface (GDDI). The complex was divided into small fragments (one residue/ligand per fragment) called a monomer, and then all fragments were performed in a parallel manner by the molecular orbital (MO) calculation [43]. Each pair interaction of monomers (I and J) was computed the PIE by a summation of several energy contributions among the clustered residues to identify the essential interacted residue for ligand binding by the following equation:

$$\mathrm{P}\mathrm{I}\mathrm{E}=\mathrm{\Delta }{E}_{\mathit{IJ}}^{\mathit{ES}}+\mathrm{\Delta }{E}_{\mathit{IJ}}^{\mathit{CT}+mix}+\mathrm{\Delta }{E}_{\mathit{IJ}}^{\mathit{DI}}+\mathrm{\Delta }{E}_{\mathit{IJ}}^{\mathit{EX}}+\mathrm{\Delta }{G}_{\mathit{Sol}}^{\mathit{PCM}}$$ (1)

where $E_{\mathit{IJ}}^{\mathit{ES}}$ is electrostatic interaction, $E_{\mathit{IJ}}^{\mathit{CT}+mix}$ is charge transfer with higher-order mixed terms energies $E_{\mathit{IJ}}^{\mathit{DI}}$dispersion, $E_{\mathit{IJ}}^{\mathit{EX}}$ is exchange-repulsion, and $G_{\mathit{Sol}}^{\mathit{PCM}}$ is the polarizable continuum model (PCM) solvation effect [44], [45], [46].

CRediT authorship contribution statement

Peerapon Deetanya: Methodology, Investigation, Writing - review & editing. Kowit Hengphasatporn: Methodology, Investigation, Writing - original draft, Writing - review & editing, Visualization. Patcharin Wilasluck: Methodology, Investigation, Validation. Yasuteru Shigeta: Methodology, Investigation, Resources, Funding acquisition. Thanyada Rungrotmongkol: Methodology, Investigation, Writing - review & editing, Resources, Funding acquisition. Kittikhun Wangkanont: Conceptualization, Methodology, Investigation, Writing - original draft, Writing - review & editing, Project administration, Funding acquisition, Supervision, Resources.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.